Fractyl Health, Inc. (NASDAQ:GUTS) Given Average Recommendation of “Hold” by Analysts

Fractyl Health, Inc. (NASDAQ:GUTS) has received an average recommendation of “Hold” from the five research firms that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have assigned a buy recommendation to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $5.40.

GUTS has been the topic of several analyst reports. Weiss Ratings restated a “sell (e+)” rating on shares of Fractyl Health in a research note on Tuesday, May 12th. HC Wainwright restated a “buy” rating and issued a $8.00 price target on shares of Fractyl Health in a research note on Thursday, June 4th. Canaccord Genuity Group restated a “buy” rating and issued a $8.00 price target on shares of Fractyl Health in a research note on Thursday, March 26th. Finally, Wall Street Zen upgraded shares of Fractyl Health from a “strong sell” rating to a “hold” rating in a research note on Saturday, May 16th.

Institutional Investors Weigh In On Fractyl Health

Several large investors have recently made changes to their positions in GUTS. Nantahala Capital Management LLC acquired a new stake in shares of Fractyl Health in the third quarter valued at approximately $19,298,000. Alyeska Investment Group L.P. acquired a new position in shares of Fractyl Health during the third quarter valued at approximately $8,981,000. Rosalind Advisors Inc. acquired a new position in shares of Fractyl Health during the third quarter valued at approximately $7,950,000. Woodline Partners LP increased its stake in shares of Fractyl Health by 821.1% during the third quarter. Woodline Partners LP now owns 5,506,534 shares of the company’s stock valued at $8,755,000 after acquiring an additional 4,908,693 shares during the period. Finally, General Catalyst Group Management LLC acquired a new position in shares of Fractyl Health during the second quarter valued at approximately $7,912,000.

Fractyl Health Price Performance

Shares of NASDAQ:GUTS opened at $0.66 on Wednesday. The firm’s 50 day moving average is $0.67 and its two-hundred day moving average is $1.08. Fractyl Health has a 52 week low of $0.38 and a 52 week high of $2.90. The firm has a market capitalization of $105.36 million, a P/E ratio of -0.51 and a beta of 2.34. The company has a current ratio of 4.28, a quick ratio of 4.28 and a debt-to-equity ratio of 1.41.

Fractyl Health (NASDAQ:GUTS) last announced its quarterly earnings results on Tuesday, May 12th. The company reported $0.06 EPS for the quarter, beating the consensus estimate of ($0.17) by $0.23. Analysts anticipate that Fractyl Health will post -0.6 earnings per share for the current year.

About Fractyl Health

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.